Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

NCT03951077 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03951077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03951077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2019
Completion date
February 10, 2021
Enrollment
118 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic ovary syndrome